



Synthorx to Present at Upcoming Investor Conferences

November 13, 2019

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at multiple upcoming investor conferences:

Jefferies London Healthcare Conference

Date: November 20, 2019
Time: 9:20 a.m. BT (4:20 a.m. ET)
Location: London, UK

Stifel 2019 Healthcare Conference

Date: November 20, 2019
Time: 10:20 a.m. ET
Location: New York, NY

Evercore ISI 2nd Annual HealthCONx Conference

Date: December 3, 2019
Time: 2:20 p.m. ET
Location: Boston, MA

Live webcasts of the company's presentations will be available at Synthorx' investor relations [website](#). An archived replay will be available for 60 days following the presentation.

To receive Synthorx' press releases and other investor information, please visit the [Investor Relations page](#) of the Company's website and register for [email alerts](#).

About Synthorx

Synthorx, Inc. is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx' proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins™. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company's lead immuno-oncology (IO) product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries by Dr. Floyd Romesberg and The Scripps Research Institute. Synthorx is headquartered in La Jolla, Calif. For more information, visit www.synthorx.com.

Investor Relations Contacts:

Enoch Kariuki, Pharm.D.
Synthorx, Inc.
ekariuki@synthorx.com
858-750-4750

Christina Tartaglia
Stern IR, Inc.
christina.tartaglia@sternir.com
212-362-1200

Media Relations Contact:

Lauren Fish
Canale Communications
lauren@canalecomm.com
619-849-5386



Source: Synthorx, Inc.